Cocaine use disorder is one of the most stubborn challenges in addiction medicine. Researchers have now studied psilocybin treatment for cocaine use disorder, and the early findings are generating real interest. Unlike opioid or alcohol dependence, cocaine addiction has no approved medication. For decades, scientists and clinicians have been searching for a breakthrough.

A clinical trial published in JAMA Network Open in May 2026 has attracted considerable attention. Researchers at the University of Alabama at Birmingham examined whether a single dose of psilocybin, paired with structured psychotherapy, could help people stop using cocaine. The results were striking, though the authors urge caution.

How the Psilocybin and Cocaine Use Disorder Trial Worked

Researchers enrolled 40 adults who met the criteria for cocaine dependence. Each participant reported using cocaine on at least four separate days in the prior month and expressed a genuine desire to quit. Most participants were Black men with lower incomes, a demographic rarely included in psychedelic research. The researchers chose this group deliberately and considered it a meaningful strength of the study.

Each participant received either a single oral dose of psilocybin (25 mg per 70 kg of body weight) or an active placebo. Both groups completed a structured psychotherapy programme, roughly one month before and one month after their full day drug session. Researchers tracked outcomes over 180 days after treatment ended. They verified cocaine use reported by participants with urine samples at every visit.

Key Findings From the Psilocybin Treatment Study

The psilocybin group outperformed the placebo group across all three primary outcomes.

Psilocybin participants reported around 29 percentage points more cocaine free days than placebo participants. Six of the 20 psilocybin participants (30%) stayed completely abstinent from cocaine through day 180. None of the placebo participants achieved the same result. The psilocybin group was roughly 18 times more likely to reach complete abstinence. Their risk of relapsing to cocaine use was also 72% lower over time.

No serious adverse events occurred in either group. During the full day session, some psilocybin participants experienced temporary blood pressure increases, emotional distress, and crying. All of these resolved without lasting consequences.

Why These Results Matter

Global cocaine use reached record levels in 2023. An estimated 25 million people used cocaine in the past year, according to the United Nations Office on Drugs and Crime. Deaths from cocaine overdose in the United States rose sharply between 2019 and 2024. The absence of any approved medication for cocaine use disorder makes this a serious public health gap.

The significance of this trial goes beyond the statistics. A 2025 systematic review found that participants in US based psychedelic trials typically come from higher socioeconomic backgrounds. This trial actively included lower income participants and Black adults, who bear a disproportionate burden of cocaine related harm. Demonstrating that psilocybin treatment for cocaine use disorder can work in this population matters enormously.

What the Research Does Not Confirm

The authors are candid about the study’s limitations. Only 40 people took part, which is a small sample. The confidence intervals around key estimates are wide. The lead researcher also served as the primary therapist. The team acknowledges this as a potential source of bias. They used a structured therapy manual to reduce this risk, but it remains a limitation.

Blinding also proved difficult, as it almost always does in psychedelic research. Psilocybin produces distinctive effects, and most participants who received it correctly identified that they had. This may have shaped their expectations and, in turn, their outcomes.

The research team describes the findings as preliminary rather than confirmatory. Scientists need larger, more rigorously controlled trials before anyone draws firm conclusions about psilocybin as a cocaine treatment.

What This Research Does Not Mean for Everyday Life

This research does not suggest people should seek out psilocybin independently. The outcomes in this trial came from a tightly controlled clinical environment. Trained clinicians supervised participants throughout the full day session. Participants also completed weeks of preparatory therapy and structured follow up sessions. Removing any of those elements changes the picture entirely.

Cocaine use disorder carries serious risks to physical and mental health. Professional support through established services remains the most important step anyone can take. Early intervention, community support, and behavioural treatments form the foundation of effective care.

What Happens Next

The study’s authors call for larger trials across more diverse populations. They also recommend closer monitoring of psychotherapy fidelity and exploration of optimal dosing strategies. Filament Health, a drug development company focused on psychedelics for stimulant use disorder, now holds rights to the trial data and aims to seek regulatory authorisation.

Psilocybin research is moving quickly. Its potential applications in mental health and addiction treatment attract serious attention from scientists and regulators alike. The path from a promising early trial to a safe and widely available treatment is long, and it must be navigated carefully.

For anyone currently struggling with cocaine use, the message from this research is one of cautious hope. Science is actively looking for new answers, and support is available right now through existing services.

Source: jamanetwork